俄罗斯国家工程院外籍院士； 美国昆泰跨国公司第一任大中国区董事长； 昆翎医药发展有限公司创始人兼CSO； 担任百华协会（Bayhelix）董事； 曾任美国华人生物医药科技协会会长； 美中药协执行董事； “千人计划”专家联谊会秘书长； 中国医药创新促进会药物研发专业委员会主任委员（第一届） 同时任国家“十一五“，”十二五”及“十三五”重大新药创制计划评审专家, 并参与国家食品药品监督管理总局药审中心的技术指南制订，新药临床评审及药审人员培训工作。

Foreign Member of the Russian Academy of Engineering Former First Chairman of Greater China Region at Quintiles Transnational Founder & CSO of Clinchoice (Tianjin) Pharmaceutical Development Co., Ltd. Serves as a Director of Bayhelix. Former President of Chinese Biopharmaceutical Association, USA (CBA). Executive Director of Sino-American Pharmaceutical Professionals Association (SAPA). Secretary of the Expert Association underthe "Thousand Talents Plan" . Chairman of the Drug Research and Development Committee (1st Session), China Pharmaceutical Innovation and Research Development Association. He also served as a review expert for the National Major New Drug Creation Program during the Eleventh, Twelfth and Thirteenth Five-Year Plans. He participated in the formulation of technical guidelines, clinical review of new drugs, and training of drug review staff at the Center for Drug Evaluation of the China Food and Drug Administration

曾任中国海洋大学特聘教授； 国家千人计划特聘专家； 国家海洋实验室人才卓越科学博导。 承担包括国家重大新药创制科技重大专项在内的各类纵向课题数十项，累计获批经费约1700万元。 在抗糖尿病药物开发方面的突破，被美国诺华（Novartis）药业斥资1.57亿美元收购，并进入临床实验。此外，抗肿瘤一类新药 SL01、抗肿瘤海洋I类新药MBRI-001及I类抗慢性结肠炎新药MBRI-003项目的研发均获得了国家及青岛市重大创新基金支持国家及青岛市重大创新基金支持，并进行临床前或临床中研究。

He served as a distinguished professor at the Ocean University of China; Special Invited Expert of the National Thousand Talents Plan; National Marine Laboratory Outstanding Talent Scientific Supervisor. He has undertaken dozens of vertical projects, including the National Major Science and Technology Project for New Drug Innovation, with cumulative approved funding reaching approximately 17 million yuan. The breakthrough in the development of anti-diabetic drugs was acquired by Novartis Pharmaceuticals in the U.S. for $157 million and proceeded to clinical trials. Additionally, the research and development of new Category I anti-tumor drugs SL01, new Category I marine anti-tumor drugs MBRI-001, and new Category I drugs MBRI-003 for chronic colitis were supported by the National and Qingdao Major Innovation Funds, with preclinical or clinical studies underway.

曾任美国莫里尼亚生物制药公司研究员、广西药用植物研究所药用资源开发中心首席专家、北京亿利生物工程技术研究所所长、美国基尼盖茨公司CTO，国家千人计划生物医药领军人物；获国家药监局签发的新药证书、新药临床批件、医疗器械注册证25项，申请国家发明专利70余项，承担科技部中小企业创新基金2项、国家发改委国家产业化示范工程2项、参与起草1项国家行业标准，并有多项国外、国内填补空白项目。

He has served as a Professor at Morinaga Biopharmaceutical Company in the U.S., outstanding Professor of the Medicinal Resources Development Center at Guangxi Institute of Medicinal Plant Research, director of Beijing Yili Biotechnology Engineering Institute, and CTO of Genie Gates Company in the U.S. He is a leading scientist in the biopharmaceutical field under the National Thousand Talents Program. He has obtained 25 new drug certificates, clinical approval documents for new drugs, and medical device registration certificates issued by the National Medical Products Administration, applied for over 70 national invention patents, undertaken two projects under the Ministry of Science and Technology's Small and Medium Enterprise Innovation Fund, two national industrialization demonstration projects under the National Development and Reform Commission, participated in drafting one national industry standard, and led multiple projects that filled domestic and international gaps.